IL278615A - - Google Patents

Info

Publication number
IL278615A
IL278615A IL27861520A IL27861520A IL278615A IL 278615 A IL278615 A IL 278615A IL 27861520 A IL27861520 A IL 27861520A IL 27861520 A IL27861520 A IL 27861520A IL 278615 A IL278615 A IL 278615A
Authority
IL
Israel
Application number
IL27861520A
Other languages
English (en)
Other versions
IL278615B1 (en
IL278615B2 (en
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of IL278615A publication Critical patent/IL278615A/en
Publication of IL278615B1 publication Critical patent/IL278615B1/en
Publication of IL278615B2 publication Critical patent/IL278615B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/57—IFN-gamma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Biomedical Technology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
IL278615A 2018-05-14 2019-05-14 Activatable interleukin 12 polypeptides and methods of using them IL278615B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862671225P 2018-05-14 2018-05-14
US201862756515P 2018-11-06 2018-11-06
US201862756507P 2018-11-06 2018-11-06
US201862756504P 2018-11-06 2018-11-06
PCT/US2019/032322 WO2019222296A1 (en) 2018-05-14 2019-05-14 Activatable interleukin 12 polypeptides and methods of use thereof

Publications (3)

Publication Number Publication Date
IL278615A true IL278615A (https=) 2021-01-31
IL278615B1 IL278615B1 (en) 2025-10-01
IL278615B2 IL278615B2 (en) 2026-02-01

Family

ID=66770569

Family Applications (2)

Application Number Title Priority Date Filing Date
IL278615A IL278615B2 (en) 2018-05-14 2019-05-14 Activatable interleukin 12 polypeptides and methods of using them
IL322964A IL322964A (en) 2018-05-14 2019-05-14 Activatable interleukin 12 polypeptides and methods of using them

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL322964A IL322964A (en) 2018-05-14 2019-05-14 Activatable interleukin 12 polypeptides and methods of using them

Country Status (12)

Country Link
US (4) US10696723B2 (https=)
EP (2) EP3794023A1 (https=)
JP (6) JP7497340B2 (https=)
KR (2) KR20210021468A (https=)
CN (2) CN112654635A (https=)
AU (6) AU2019271147A1 (https=)
BR (2) BR112020023167A2 (https=)
CA (2) CA3100005A1 (https=)
IL (2) IL278615B2 (https=)
MX (3) MX2020012252A (https=)
SG (2) SG11202011309SA (https=)
WO (2) WO2019222296A1 (https=)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019008727A2 (pt) 2016-11-28 2019-07-16 Chugai Seiyaku Kabushiki Kaisha domínio de ligação ao antígeno, e polipeptídeo incluindo seção de transporte
JP7626577B2 (ja) 2016-11-28 2025-02-07 中外製薬株式会社 リガンド結合活性が調整可能なリガンド結合分子
JP2020530280A (ja) 2017-07-03 2020-10-22 トルク セラピューティクス， インコーポレイテッド 免疫刺激性融合分子およびその使用
JP7482630B2 (ja) 2017-11-28 2024-05-14 中外製薬株式会社 抗原結合ドメインおよび運搬部分を含むポリペプチド
TWI880235B (zh) 2017-11-28 2025-04-11 日商中外製藥股份有限公司 可調整配體結合活性的配體結合分子
AU2019232729B2 (en) 2018-03-05 2024-08-08 The University Of Chicago Methods and compositions for treating cancer with ECM-affinity peptides linked to cytokines
AU2019271148B9 (en) * 2018-05-14 2025-05-29 Werewolf Therapeutics, Inc. Activatable interleukin-2 polypeptides and methods of use thereof
WO2019222296A1 (en) * 2018-05-14 2019-11-21 Werewolf Therapeutics, Inc. Activatable interleukin 12 polypeptides and methods of use thereof
WO2020023702A1 (en) 2018-07-25 2020-01-30 AskGene Pharma, Inc. Novel il-21 prodrugs and methods of use thereof
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
US20220002370A1 (en) * 2018-09-27 2022-01-06 Xilio Development, Inc. Masked cytokine polypeptides
CN113710229B (zh) 2019-02-25 2026-01-06 芝加哥大学 用与抗炎剂连接的ecm亲和肽治疗炎症性和自身免疫性病症的方法和组合物
EP3969035A4 (en) 2019-05-14 2023-06-21 Werewolf Therapeutics, Inc. SEPARATION UNITS AND METHODS AND THEIR USE
CA3141626A1 (en) 2019-06-12 2020-12-17 AskGene Pharma, Inc. Novel il-15 prodrugs and methods of use thereof
EP3997115A4 (en) * 2019-07-12 2023-11-22 Proviva Therapeutics (Hong Kong) Limited Il-2 compositions and methods of use thereof
WO2021016599A1 (en) * 2019-07-25 2021-01-28 Trutino Biosciences Inc Il-2 cytokine prodrugs comprising a cleavable linker
BR112022001320A2 (pt) * 2019-07-25 2022-04-12 Univ Chicago Composições e métodos compreendendo agentes terapêuticos ativados por protease
CA3148505A1 (en) * 2019-08-12 2021-02-18 AskGene Pharma, Inc. Novel il-2 fusion molecules
AU2020353235A1 (en) * 2019-09-28 2022-03-31 AskGene Pharma, Inc. Cytokine prodrugs and dual-prodrugs
MX2022005666A (es) 2019-11-14 2022-10-07 Werewolf Therapeutics Inc Polipeptidos de citocina activables y metodos de uso de los mismos.
WO2021122866A1 (en) 2019-12-17 2021-06-24 Ose Immunotherapeutics Bifunctional molecules comprising an il-7 variant
CA3165927A1 (en) 2020-01-11 2021-07-15 AskGene Pharma, Inc. Novel masked cytokines and methods of use thereof
EP4093875A4 (en) * 2020-01-20 2024-02-28 Chugai Seiyaku Kabushiki Kaisha Ligand-binding fusion proteins
US20210252142A1 (en) * 2020-02-06 2021-08-19 Aetio Biotherapy, Inc. Compositions and methods for treating viral infections
JP7773991B2 (ja) * 2020-03-23 2025-11-20 ザイムワークス ビーシー インコーポレイテッド マスクされたｉｌ１２融合タンパク質及びその使用方法
JP7771076B2 (ja) * 2020-04-01 2025-11-17 エクシリオ デベロップメント， インコーポレイテッド マスクされたｉｌ－１２サイトカイン及びその切断産物
WO2021207669A1 (en) * 2020-04-10 2021-10-14 Cytomx Therapeutics, Inc. Activatable cytokine constructs and related compositions and methods
EP4143220A4 (en) * 2020-04-30 2024-05-29 Immune Targeting Inc. COMPOSITION OF ACTIVATABLE IL2 AND METHODS OF USE
IL298136A (en) 2020-05-13 2023-01-01 Bonum Therapeutics Inc Preparations of protein complexes and methods of using them
CA3178657A1 (en) * 2020-05-19 2021-11-25 William Winston Activatable il-12 polypeptides and methods of use thereof
WO2021262985A1 (en) * 2020-06-25 2021-12-30 Amunix Pharmaceuticals, Inc. Cytokine conjugates
CA3186753A1 (en) 2020-07-20 2022-01-27 John Mumm Dual cytokine fusion proteins comprising il-10
JP2023540629A (ja) * 2020-09-16 2023-09-25 ベイジーン リミテッド インターロイキン１５構築物及び使用方法
WO2022115865A2 (en) 2020-11-25 2022-06-02 Xilio Development, Inc. Tumor-specific cleavable linkers
KR20230118887A (ko) 2020-12-03 2023-08-14 센츄리 쎄라퓨틱스 인코포레이티드 유전자 조작 세포 및 이의 용도
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
AR124414A1 (es) 2020-12-18 2023-03-22 Century Therapeutics Inc Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable
WO2022155263A2 (en) * 2021-01-12 2022-07-21 Askgene Pharma Inc. Chimeric molecules comprising il-12 agonist polypeptide
BR112023018735A2 (pt) 2021-03-16 2023-11-28 Cytomx Therapeutics Inc Construtos de citocinas ativáveis mascarados e composições e métodos relacionados
MX2023012489A (es) * 2021-04-22 2023-11-22 Guangdong Fapon Biopharma Inc Polipeptido de fusion biespecifico multifuncional.
US20240228586A1 (en) * 2021-05-07 2024-07-11 The University Of Chicago Compositions and methods comprising protease-activated therapeutic agents
AU2022314734A1 (en) * 2021-07-19 2024-02-08 Regeneron Pharmaceuticals, Inc. Il12 receptor agonists and methods of use thereof
WO2023023065A1 (en) * 2021-08-17 2023-02-23 Werewolf Therapeutics, Inc. Inducible cytokine prodrug and pd-1/pd-l1 combination therapy
WO2023034825A1 (en) * 2021-08-30 2023-03-09 Cytomx Therapeutics, Inc. Method for determining protease activity in a biological sample
AR127343A1 (es) * 2021-10-13 2024-01-31 Cytomx Therapeutics Inc Construcciones de citoquinas activables triméricas y composiciones y métodos relacionados
CA3234552A1 (en) 2021-10-20 2023-04-27 Synthekine, Inc. Heterodimeric fc cytokines and uses thereof
WO2023070038A2 (en) * 2021-10-20 2023-04-27 Synthekine, Inc. Human il-12p40 variants and uses thereof
WO2023114775A2 (en) * 2021-12-13 2023-06-22 Deka Biosciences, Inc. Dual cytokine fusion proteins comprising multi-subunit cytokines
WO2023154785A2 (en) * 2022-02-10 2023-08-17 Orionis Biosciences, Inc. Il-2 trap molecules
JP7842232B2 (ja) * 2022-02-18 2026-04-07 江蘇衆紅生物工程創薬研究院有限公司 生物活性分子の活性放出制御及び活性徐放を達成する方法及びその薬物への応用
AU2023226005A1 (en) * 2022-02-23 2024-08-29 Bright Peak Therapeutics Ag Activatable il-18 polypeptides
WO2023196897A1 (en) * 2022-04-07 2023-10-12 Werewolf Therapeutics Inc. Il-12 prodrugs
CN120051483A (zh) * 2022-08-18 2025-05-27 再生元制药公司 干扰素前蛋白及其用途
EP4633740A2 (en) * 2022-12-12 2025-10-22 Harpoon Therapeutics, Inc. Integrin beta 6 (itgb6) targeting trispecific protein for treatment of cancer
WO2024147891A1 (en) * 2023-01-03 2024-07-11 Harpoon Therapeutics, Inc. Nectin4 targeting trispecific protein for treatment of cancer
US20240376170A1 (en) 2023-01-11 2024-11-14 Bright Peak Therapeutics Ag Conditionally activated proteins and methods of use
US20240417436A1 (en) 2023-01-11 2024-12-19 Bright Peak Therapeutics Ag Conditionally activated immunocytokines and methods of use
CN118359730A (zh) * 2023-01-17 2024-07-19 上海君赛生物科技有限公司 包含细胞因子的靶向型融合蛋白
WO2024211779A1 (en) * 2023-04-05 2024-10-10 The Regents Of The University Of California Affinity peptides for diagnosis and treatment of viral infections
WO2024216053A1 (en) * 2023-04-12 2024-10-17 The Board Of Trustees Of The Leland Stanford Junior University Small molecule control of membrane and secreted proteins via human proteases
AU2024258970A1 (en) * 2023-04-17 2025-10-23 ZAG Bio, Inc. Tissue-directed antibodies and methods of using the same
CN121772937A (zh) * 2023-05-30 2026-03-31 治疗调适公司 包含白细胞介素和钙化合物的用于治疗癌症的组合物
AU2024321345A1 (en) 2023-08-10 2026-01-29 Werewolf Therapeutics, Inc. Activatable il-10 polypeptides and methods of use thereof
WO2025041101A1 (en) 2023-08-23 2025-02-27 Bright Peak Therapeutics Ag Activatable il-18 immunocytokines and uses thereof
WO2025072450A1 (en) 2023-09-26 2025-04-03 Werewolf Therapeutics, Inc. Enhanced adoptive cell therapy
WO2025072443A2 (en) 2023-09-26 2025-04-03 Werewolf Therapeutics, Inc. Activatable il-21 polypeptides and methods of use thereof and single domain human serum albumin antibodies
WO2025114529A1 (en) 2023-12-01 2025-06-05 Ablynx Nv Multispecific antibodies recognising human serum albumin, tcr and a tumor antigen recognising moiety
WO2025122957A1 (en) * 2023-12-08 2025-06-12 Amunix Pharmaceuticals, Inc. Protease activatable cytokines and methods for making and using the same
WO2025151273A1 (en) 2024-01-08 2025-07-17 Adimab, Llc Il-18 polypeptides and uses thereof
WO2025151274A1 (en) 2024-01-08 2025-07-17 Adimab, Llc Inducible il-18 prodrugs
CN120230225A (zh) * 2024-02-07 2025-07-01 上海交通大学 活性可调节的il-12融合蛋白及其用途
WO2026020161A1 (en) * 2024-07-19 2026-01-22 Cytomx Therapeutics, Inc. Activatable il-12 constructs and related compositions and methods
WO2026072455A1 (en) 2024-09-26 2026-04-02 Werewolf Therapeutics, Inc. Single domain human serum albumin antibodies
WO2026083296A1 (en) 2024-10-16 2026-04-23 Bright Peak Therapeutics Ag Trispecific compositions comprising il-18, vegf binding domains, and pd-1 binding domains
WO2026083295A1 (en) 2024-10-16 2026-04-23 Bright Peak Therapeutics Ag Trispecific compositions comprising il-2, vegf binding domains, and pd-1 binding domains

Family Cites Families (187)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5770701A (en) 1987-10-30 1998-06-23 American Cyanamid Company Process for preparing targeted forms of methyltrithio antitumor agents
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
ATE135397T1 (de) 1988-09-23 1996-03-15 Cetus Oncology Corp Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
US5089261A (en) 1989-01-23 1992-02-18 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
US5891693A (en) 1990-01-25 1999-04-06 Alusuisse Holdings A.G. Recombinant DNA methods vectors and host cells
EP0547163B1 (en) 1990-08-29 2002-02-06 Centre Hospitalier Regional De Nantes Protein polyligands joined to a stable protein core
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US5650150A (en) 1990-11-09 1997-07-22 Gillies; Stephen D. Recombinant antibody cytokine fusion proteins
US5508192A (en) 1990-11-09 1996-04-16 Board Of Regents, The University Of Texas System Bacterial host strains for producing proteolytically sensitive polypeptides
US5264365A (en) 1990-11-09 1993-11-23 Board Of Regents, The University Of Texas System Protease-deficient bacterial strains for production of proteolytically sensitive polypeptides
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
US7018809B1 (en) 1991-09-19 2006-03-28 Genentech, Inc. Expression of functional antibody fragments
FI941572A7 (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
CA2372813A1 (en) 1992-02-06 1993-08-19 L.L. Houston Biosynthetic binding protein for cancer marker
CA2118508A1 (en) 1992-04-24 1993-11-11 Elizabeth S. Ward Recombinant production of immunoglobulin-like domains in prokaryotic cells
DK0752248T3 (da) 1992-11-13 2000-11-13 Idec Pharma Corp Terapeutisk anvendelse af kimæriske og radioaktivt mærkede antistoffer mod humant B-lymfocytbegrænset differentieringsantig
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5639635A (en) 1994-11-03 1997-06-17 Genentech, Inc. Process for bacterial production of polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
AU2660397A (en) 1996-04-05 1997-10-29 Board Of Regents, The University Of Texas System Methods for producing soluble, biologically-active disulfide bond-containing eukaryotic proteins in bacterial cells
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
DE19701141C1 (de) * 1997-01-16 1998-04-09 Hoechst Ag Genkonstrukte für durch Proteasen aktivierbare Wirksubstanzen
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6083715A (en) 1997-06-09 2000-07-04 Board Of Regents, The University Of Texas System Methods for producing heterologous disulfide bond-containing polypeptides in bacterial cells
ES2244066T3 (es) 1997-06-24 2005-12-01 Genentech, Inc. Procedimiento y composiciones de glicoproteinas galactosiladas.
AU759779B2 (en) 1997-10-31 2003-05-01 Genentech Inc. Methods and compositions comprising glycoprotein glycoforms
ATE375365T1 (de) 1998-04-02 2007-10-15 Genentech Inc Antikörper varianten und fragmente davon
DK1071700T3 (da) 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
CA2704600C (en) 1999-04-09 2016-10-25 Kyowa Kirin Co., Ltd. A method for producing antibodies with increased adcc activity
IT1306736B1 (it) 1999-10-29 2001-10-02 Benito Salmi Dispositivo di contenimento e distribuzione di palloni per tiri alvolo.
US6399219B1 (en) 1999-12-23 2002-06-04 Vapor Technologies, Inc. Article having a decorative and protective coating thereon
AU767394C (en) 1999-12-29 2005-04-21 Immunogen, Inc. Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use
EP2213743A1 (en) 2000-04-12 2010-08-04 Human Genome Sciences, Inc. Albumin fusion proteins
US20040014652A1 (en) 2000-06-01 2004-01-22 Andre Trouet Tumor activated prodrug compounds and methods of making and using the same
DE10045592A1 (de) 2000-09-15 2002-03-28 Klaus Pfizenmaier Ein Antikörper-TNF-TNF Inhibitor Fusionsprotein (TNF-Selektokin) als zielspezifisches Prozytokin zur Tumortherapie
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
CA2430013C (en) 2000-11-30 2011-11-22 Medarex, Inc. Transgenic transchromosomal rodents for making human antibodies
US7083784B2 (en) 2000-12-12 2006-08-01 Medimmune, Inc. Molecules with extended half-lives, compositions and uses thereof
US6942853B2 (en) 2001-01-09 2005-09-13 Queen Mary And Westfield College Latent fusion protein
AU2002335930B2 (en) 2001-03-09 2005-07-28 Morphosys Ag Serum albumin binding moieties
NZ571596A (en) 2001-08-03 2010-11-26 Glycart Biotechnology Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
WO2003015697A2 (en) 2001-08-13 2003-02-27 University Of Southern California Interleukin-2 mutants with reduced toxicity
AU2002332041A1 (en) 2001-10-05 2003-04-22 Human Genome Sciences, Inc. Albumin fusion proteins
CA2463879C (en) 2001-10-25 2012-12-04 Genentech, Inc. Glycoprotein compositions
WO2003059934A2 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
AU2002364586A1 (en) 2001-12-21 2003-07-30 Delta Biotechnology Limited Albumin fusion proteins
KR101271635B1 (ko) * 2001-12-21 2013-06-12 휴먼 게놈 사이언시즈, 인코포레이티드 알부민 융합 단백질
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
EP1500400A4 (en) 2002-04-09 2006-10-11 Kyowa Hakko Kogyo Kk MEDICAMENT WITH ANTIBODY COMPOSITION
CA2481658A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Method of enhancing of binding activity of antibody composition to fcy receptor iiia
CA2481925A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Therapeutic agent for patients having human fc.gamma.riiia
ATE503829T1 (de) 2002-04-09 2011-04-15 Kyowa Hakko Kirin Co Ltd Zelle mit erniedrigter oder deletierter aktivität eines am gdp-fucosetransport beteiligten proteins
EP1498490A4 (en) 2002-04-09 2006-11-29 Kyowa Hakko Kogyo Kk PROCESS FOR PREPARING ANTIBODY COMPOSITION
EP1539941A4 (en) * 2002-08-27 2006-11-29 ADZYMES AND THEIR USES
US8809504B2 (en) 2002-09-03 2014-08-19 Vit Lauermann Inhibitor which is deactivatable by a reagent produced by a target cell
CN1703423A (zh) 2002-10-14 2005-11-30 豪夫迈－罗氏公司 Il－15拮抗剂
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
WO2004041863A2 (en) 2002-11-08 2004-05-21 Ablynx N.V. Single domain antibodies directed against interferon- gamma and uses therefor
TWI335821B (en) 2002-12-16 2011-01-11 Genentech Inc Immunoglobulin variants and uses thereof
UA90654C2 (ru) * 2002-12-26 2010-05-25 Маунтин Вью Фармасьютикалз, Инк. Полимерные конъюгаты интерферона-бета с повышенной биологической активностью
GEP20084487B (en) 2002-12-26 2008-09-25 Mountain View Pharmaceuticals Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof
US7625998B2 (en) 2003-04-09 2009-12-01 Asterion Limited Cytokine polypeptides and antibodies containing a signal sequence for the attachment of glycosylphosphatidylinositol
US7569215B2 (en) 2003-07-18 2009-08-04 Massachusetts Institute Of Technology Mutant interleukin-2 (IL-2) polypeptides
JPWO2005035586A1 (ja) 2003-10-08 2007-11-22 協和醗酵工業株式会社 融合蛋白質組成物
JPWO2005035778A1 (ja) 2003-10-09 2006-12-21 協和醗酵工業株式会社 α１，６−フコシルトランスフェラーゼの機能を抑制するＲＮＡを用いた抗体組成物の製造法
EP2478912B1 (en) 2003-11-06 2016-08-31 Seattle Genetics, Inc. Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy
WO2005053742A1 (ja) 2003-12-04 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. 抗体組成物を含有する医薬
HUE027902T2 (en) 2004-02-09 2016-11-28 Human Genome Sciences Inc Corp Service Company Albumin fusion proteins
AU2006232287B2 (en) 2005-03-31 2011-10-06 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
WO2006110728A2 (en) 2005-04-12 2006-10-19 The Uab Research Foundation Immunogenic cmv tegument aggregates
US20070269422A1 (en) 2006-05-17 2007-11-22 Ablynx N.V. Serum albumin binding proteins with long half-lives
WO2007146038A2 (en) 2006-06-07 2007-12-21 Human Genome Sciences, Inc. Albumin fusion proteins
EP1867660A1 (en) * 2006-06-14 2007-12-19 CSL Behring GmbH Proteolytically cleavable fusion protein comprising a blood coagulation factor
CN101557817A (zh) * 2006-09-14 2009-10-14 人类基因科学公司 清蛋白融合蛋白
WO2008033413A2 (en) 2006-09-14 2008-03-20 Human Genome Sciences, Inc. Albumin fusion proteins
US20080302732A1 (en) 2007-05-24 2008-12-11 Hyongsok Soh Integrated fluidics devices with magnetic sorting
JP2010536341A (ja) * 2007-08-15 2010-12-02 アムニクス， インコーポレイテッド 生物学的に活性なポリペプチドの特性を改変するための組成物および方法
US20090304719A1 (en) * 2007-08-22 2009-12-10 Patrick Daugherty Activatable binding polypeptides and methods of identification and use thereof
WO2009103965A1 (en) 2008-02-19 2009-08-27 Asterion Limited Modified linkers
WO2010014258A2 (en) 2008-08-01 2010-02-04 Nektar Therapeutics Al, Corporation Conjugates having a releasable linkage
GB0815216D0 (en) 2008-08-21 2008-09-24 Asterion Ltd Interleukin
RU2636046C2 (ru) 2009-01-12 2017-11-17 Сайтомкс Терапьютикс, Инк Композиции модифицированных антител, способы их получения и применения
AU2010215761B2 (en) 2009-02-23 2017-04-06 Cytomx Therapeutics, Inc Proproteins and methods of use thereof
EP2456787A4 (en) 2009-07-24 2013-01-30 Univ Leland Stanford Junior CYTOKIN COMPOSITIONS AND METHOD FOR THEIR USE
US20130064788A1 (en) 2009-10-10 2013-03-14 Eleven Biotherapeutics, Inc. Il-17 family cytokine compositions and uses
EP2553101A4 (en) * 2010-04-02 2013-09-04 Univ Rochester PROTEASE-ACTIVATED CYTOKINES
EP2556087A1 (en) 2010-04-09 2013-02-13 Novozymes Biopharma DK A/S Albumin derivatives and variants
AU2011316786A1 (en) 2010-10-22 2013-05-02 Protox Therapeutics Corp. Use of human serum albumin to decrease antigenicity of therapeutic proteins
US20130225496A1 (en) 2010-11-01 2013-08-29 Novozymes Biopharma Dk A/S Albumin Variants
WO2012065086A1 (en) 2010-11-12 2012-05-18 Nektar Therapeutics Conjugates of an il-2 moiety and a polymer
CU23923B1 (es) 2010-11-12 2013-07-31 Ct De Inmunología Molecular Polipéptidos derivados de la il-2 con actividad agonista
US20120201746A1 (en) * 2010-12-22 2012-08-09 Abbott Laboratories Half immunoglobulin binding proteins and uses thereof
CN110078827A (zh) 2012-04-27 2019-08-02 西托姆克斯治疗公司 结合表皮生长因子受体的可活化的抗体其使用方法
MX341569B (es) 2012-05-18 2016-08-25 Nippon Steel & Sumikin Texeng Co Ltd Mecanismo de separacion, robot manipulador, estanteria de almacenamiento, y metodo de separacion para separar cuchillas redondas y/o separadores.
EP2863948B1 (en) 2012-06-22 2018-10-24 Cytomx Therapeutics Inc. Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof
US9856314B2 (en) 2012-06-22 2018-01-02 Cytomx Therapeutics, Inc. Activatable antibodies having non-binding steric moieties and methods of using the same
CN104619334A (zh) 2012-08-09 2015-05-13 利兰斯坦福初级大学董事会 超级因子和合成因子:具有新的和增强的信号传导活性的经改造细胞因子
EP2882844B1 (en) 2012-08-10 2018-10-03 Cytomx Therapeutics Inc. Protease-resistant systems for polypeptide display and methods of making and using thereof
US9487590B2 (en) 2012-09-25 2016-11-08 Cytomx Therapeutics, Inc. Activatable antibodies that bind interleukin-6 receptor and methods of use thereof
WO2014100014A1 (en) 2012-12-17 2014-06-26 The Board Of Trustees Of The Leland Stanford Junior University Super-2 complexes with antibody to augment il-2 therapy
WO2014094799A1 (en) * 2012-12-19 2014-06-26 Scil-Proteins-Gmbh Ubiquitin moieties as a means for prolonging serum half-life
CN105008918A (zh) 2013-01-04 2015-10-28 西托姆克斯治疗公司 用于检测生物系统中的蛋白酶活性的组合物和方法
US9255155B2 (en) 2013-01-31 2016-02-09 The Regents Of The University Of California Antibodies specific for urokinase-type plasminogen activator and methods of treating cancer
EP2968587A2 (en) 2013-03-13 2016-01-20 Bristol-Myers Squibb Company Fibronectin based scaffold domains linked to serum albumin or a moiety binding thereto
KR20160018579A (ko) 2013-06-04 2016-02-17 싸이톰스 테라퓨틱스, 인크. 활성화가능 항체를 접합하기 위한 조성물 및 방법
CN105722859B (zh) 2013-07-25 2021-05-07 西托姆克斯治疗公司 多特异性抗体、多特异性可活化抗体及其使用方法
NZ718283A (en) 2013-09-25 2022-05-27 Cytomx Therapeutics Inc Matrix metalloproteinase substrates and other cleavable moieties and methods of use thereof
WO2015066279A2 (en) 2013-10-30 2015-05-07 Cytomx Therapeutics, Inc. Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
WO2015089283A1 (en) 2013-12-11 2015-06-18 Cytomx Therapeutics, Inc. Antibodies that bind activatable antibodies and methods of use thereof
US9562073B2 (en) 2014-01-31 2017-02-07 Cytomx Therapeutics, Inc. Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof
KR102410090B1 (ko) 2014-02-21 2022-06-16 넥타르 테라퓨틱스 (인디아) 프라이빗 리미티드 항-ｃｔｌａ－４ 항체 또는 항-ｐｄ－１ 항체와 조합한 ｉｌ－２ｒ베타-선택적 효현제
ES2736127T3 (es) * 2014-03-20 2019-12-26 Bristol Myers Squibb Co Dominios de tipo III de fibronectina de unión a seroalbúmina
WO2015164815A1 (en) 2014-04-24 2015-10-29 The Board Of Trustees Of The Leland Stanford Junior University Superagonists, partial agonists and antagonists of interleukin-2
CA2955947A1 (en) 2014-07-25 2016-01-28 Cytomx Therapeutics, Inc. Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
MA41374A (fr) 2015-01-20 2017-11-28 Cytomx Therapeutics Inc Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci
CN108112254B (zh) 2015-03-13 2022-01-28 西托姆克斯治疗公司 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法
CA2982362A1 (en) * 2015-04-10 2016-10-13 Amgen Inc. Interleukin-2 muteins for the expansion of t-regulatory cells
CN108064176A (zh) * 2015-04-22 2018-05-22 库瑞瓦格股份公司 用于治疗肿瘤疾病的含有rna的组合物
IL292798A (en) 2015-05-04 2022-07-01 Cytomx Therapeutics Inc Anti-cd166 antibodies, activatable anti-cd166 antibodies, preparations containing them and their uses
BR112017023862A2 (pt) 2015-05-04 2018-07-17 Cytomx Therapeutics Inc anticorpos anti-cd71, anticorpos anti-cd71 ativáveis, e métodos de uso destes
CA2984892A1 (en) 2015-05-04 2016-11-10 Cytomx Therapeutics, Inc. Anti-itga3 antibodies, activatable anti-itga3 antibodies, and methods of use thereof
US9708412B2 (en) 2015-05-21 2017-07-18 Harpoon Therapeutics, Inc. Trispecific binding proteins and methods of use
US20160362469A1 (en) 2015-06-12 2016-12-15 Tianxin Wang Methods for protein modification in pharmaceutical applications
MX383464B (es) 2015-07-13 2025-03-14 Cytomx Therapeutics Inc Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y métodos de uso de los mismos.
CN109071667A (zh) 2016-03-08 2018-12-21 马弗里克治疗公司 可诱导性结合蛋白和使用方法
EP3493844A4 (en) 2016-05-20 2021-03-24 Harpoon Therapeutics Inc. SINGLE DOMAIN SERUM ALBUMIN BINDING PROTEIN
US12304935B2 (en) * 2016-07-29 2025-05-20 Juno Therapeutics, Inc. Immunomodulatory polypeptides and related compositions and methods
CN106317226B (zh) * 2016-08-19 2017-09-05 安源医药科技（上海）有限公司 用于构建融合蛋白的连接肽
MY203000A (en) 2016-10-14 2024-06-01 Xencor Inc Il15/il15r� heterodimeric fc-fusion proteins
US20190225702A1 (en) 2016-10-14 2019-07-25 Harpoon Therapeutics, Inc. Innate immune cell trispecific binding proteins and methods of use
MY200695A (en) 2016-11-03 2024-01-11 Bristol Myers Squibb Co Activatable anti-ctla-4 antibodies and uses thereof
JP7626577B2 (ja) * 2016-11-28 2025-02-07 中外製薬株式会社 リガンド結合活性が調整可能なリガンド結合分子
WO2018136725A1 (en) 2017-01-19 2018-07-26 Harpoon Therapeutics, Inc. Innate immune cell inducible binding proteins and methods of use
US11535668B2 (en) 2017-02-28 2022-12-27 Harpoon Therapeutics, Inc. Inducible monovalent antigen binding protein
WO2018160877A1 (en) 2017-03-01 2018-09-07 Nektar Therapeutics Immunotherapeutic tumor treatment method using an interleukin-2 receptor alpha, beta-selective agonist in combination with adoptive cell transfer therapy
WO2018165619A1 (en) 2017-03-09 2018-09-13 Cytomx Therapeutics, Inc. Cd147 antibodies, activatable cd147 antibodies, and methods of making and use thereof
WO2018204528A1 (en) 2017-05-02 2018-11-08 Nektar Therapeutics Immunotherapeutic tumor treatment method
IL270634B2 (en) 2017-05-15 2025-06-01 Nektar Therapeutics Long-acting interleukin-15 receptor agonists and related immunotherapeutic compositions and methods
CN110914302A (zh) 2017-06-01 2020-03-24 赛托姆克斯治疗学股份有限公司 可活化抗pdl1抗体及其使用方法
JP2020528878A (ja) 2017-06-20 2020-10-01 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム がん治療用インターフェロンプロドラッグ
CN111133006A (zh) 2017-07-14 2020-05-08 西托姆克斯治疗公司 抗cd166抗体及其用途
JP2020530554A (ja) 2017-07-20 2020-10-22 シートムエックス セラピューティクス，インコーポレイテッド 活性化抗体の特性を定性的および／または定量的に分析する方法およびその使用
WO2019036031A2 (en) 2017-08-17 2019-02-21 Nektar Therapeutics IMMUNOTHERAPEUTIC METHOD FOR TUMOR TREATMENT
WO2019046652A1 (en) 2017-08-30 2019-03-07 Cytomx Therapeutics, Inc. ANTI-CD166 ACTIVABLE ANTIBODIES, AND METHODS OF USE
EP3694885A1 (en) 2017-10-14 2020-08-19 CytomX Therapeutics, Inc. Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof
WO2019094396A1 (en) 2017-11-07 2019-05-16 Nektar Therapeutics Immunotherapeutic combination for treating cancer
EP3762406A2 (en) 2018-03-09 2021-01-13 Askgene Pharma, Inc. Cytokine prodrugs
CU24554B1 (es) 2018-05-07 2021-11-04 Ct Inmunologia Molecular Proteínas de fusión compuestas por una muteína de interleucina 2 e interferón tipo 1
WO2019222296A1 (en) * 2018-05-14 2019-11-21 Werewolf Therapeutics, Inc. Activatable interleukin 12 polypeptides and methods of use thereof
AU2019271148B9 (en) * 2018-05-14 2025-05-29 Werewolf Therapeutics, Inc. Activatable interleukin-2 polypeptides and methods of use thereof
AU2019288484B2 (en) 2018-06-22 2024-06-20 Cugene Inc. Cytokine-based bioactivatable drugs and methods of uses thereof
US20220002370A1 (en) 2018-09-27 2022-01-06 Xilio Development, Inc. Masked cytokine polypeptides
CA3141626A1 (en) 2019-06-12 2020-12-17 AskGene Pharma, Inc. Novel il-15 prodrugs and methods of use thereof
WO2021016599A1 (en) 2019-07-25 2021-01-28 Trutino Biosciences Inc Il-2 cytokine prodrugs comprising a cleavable linker
CA3148505A1 (en) 2019-08-12 2021-02-18 AskGene Pharma, Inc. Novel il-2 fusion molecules
TW202204388A (zh) 2020-04-01 2022-02-01 美商艾希利歐發展股份有限公司 經遮蔽之il-2細胞激素及其裂解產物
EP4126246A4 (en) 2020-04-01 2024-05-15 Xilio Development, Inc. MASKED IL-15 CYTOKINE AND THEIR DECOMPOSITION PRODUCTS
JP7771076B2 (ja) 2020-04-01 2025-11-17 エクシリオ デベロップメント， インコーポレイテッド マスクされたｉｌ－１２サイトカイン及びその切断産物

Also Published As

Publication number Publication date
WO2019222294A1 (en) 2019-11-21
AU2019271147A1 (en) 2020-12-17
MX2020012248A (es) 2021-04-28
US12275769B2 (en) 2025-04-15
US20200283489A1 (en) 2020-09-10
JP2021523741A (ja) 2021-09-09
CN112654636A (zh) 2021-04-13
AU2023204112B2 (en) 2025-03-13
AU2025213642A1 (en) 2025-08-28
JP2023178475A (ja) 2023-12-14
IL322964A (en) 2025-10-01
BR112020023167A2 (pt) 2021-02-09
SG11202011309SA (en) 2020-12-30
IL278615B1 (en) 2025-10-01
JP2021524756A (ja) 2021-09-16
US20190367576A1 (en) 2019-12-05
MX2025003225A (es) 2025-04-02
AU2023204112A1 (en) 2023-07-20
WO2019222296A1 (en) 2019-11-21
AU2023237030B2 (en) 2025-07-10
AU2025203522A9 (en) 2026-03-12
US10696723B2 (en) 2020-06-30
JP2025078751A (ja) 2025-05-20
AU2025203522A1 (en) 2025-06-05
JP2023182849A (ja) 2023-12-26
EP3794022A1 (en) 2021-03-24
JP7497340B2 (ja) 2024-06-10
CA3100005A1 (en) 2019-11-21
CN112654635A (zh) 2021-04-13
KR20210021468A (ko) 2021-02-26
SG11202011308VA (en) 2020-12-30
JP7766662B2 (ja) 2025-11-10
US20250179138A1 (en) 2025-06-05
AU2019271149A1 (en) 2020-12-17
MX2020012252A (es) 2021-04-28
JP2026016843A (ja) 2026-02-03
AU2019271149B2 (en) 2023-07-13
KR20210020907A (ko) 2021-02-24
EP3794023A1 (en) 2021-03-24
US20220324930A1 (en) 2022-10-13
BR112020023118A2 (pt) 2021-04-13
AU2023237030A1 (en) 2023-10-12
CA3100018A1 (en) 2019-11-21
US11453710B2 (en) 2022-09-27
IL278615B2 (en) 2026-02-01

Similar Documents

Publication Publication Date Title
BR112021012225A2 (https=)
BR112021008873A2 (https=)
BR122022006221A2 (https=)
BR112021000792B8 (https=)
BR122022015534A2 (https=)
BR122022002102A2 (https=)
AT524834A2 (https=)
AT524874A5 (https=)
AU2018438767B1 (https=)
AT521543A3 (https=)
AT524266A2 (https=)
AT524961A5 (https=)
BR122022005529A2 (https=)
BR122022016585A2 (https=)
BR212020012832U2 (https=)
BR202018071071U8 (https=)
BR102018070765A2 (https=)
BR102018016915A2 (https=)
BE2018C025I2 (https=)
BR112020025288A2 (https=)
BR202018008879U2 (https=)
BR202018007669U2 (https=)
BR102018007062A2 (https=)
BR202018006247U2 (https=)
BR202018004136U2 (https=)